ALLMedicine™ Hypogammaglobulinemia Center
Research & Reviews 672 results
https://www.mdedge.com/hematology-oncology/article/262059/cll/b-cell-cancers-sparse-insight-preventing-infections
Randy Dotinga
Mar 28th, 2023 - Cases of acquired hypogammaglobulinemia are expected to rise, as patients live longer with such B-cell malignancies as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, and multiple myeloma. But there’s a striking shortage of research into.
https://doi.org/10.1007/s10067-023-06559-y
Clinical Rheumatology; Modica RF, Thatayatikom A et. al.
Mar 28th, 2023 - Childhood-onset neuropsychiatric systemic lupus erythematosus (cNPSLE) with psychosis is a challenging manifestation of SLE. Pathogenic long-lived plasma cells (LLPCs) are not specifically targeted by standard immunosuppression and their persisten...
https://doi.org/10.1111/1756-185X.14676
International Journal of Rheumatic Diseases; Armağan B, Konak HE et. al.
Mar 22nd, 2023 - Rituximab, which is used in autoimmune rheumatic diseases (ARD), can cause both an increased risk of development of COVID-19 disease and re-infection due to its potent and long-acting immunosuppression. So, we aimed to evaluate the frequency, risk...
https://emedicine.medscape.com/article/1001332-treatment
Mar 20th, 2023 - Approach Considerations Emergency care for acute bronchitis or exacerbation of chronic bronchitis must focus on ensuring that the child has adequate oxygenation and hydration. Outpatient care is appropriate unless bronchitis is complicated by seve...
https://emedicine.medscape.com/article/1001332-clinical
Mar 20th, 2023 - History Acute bronchitis begins as a respiratory tract infection that manifests as the common cold. Symptoms often include coryza, malaise, chills, slight fever, sore throat, and back and muscle pain. The cough in these children is usually accompa...
Drugs 11 results see all →
Clinicaltrials.gov 44 results
https://clinicaltrials.gov/ct2/show/NCT04805203
Mar 2nd, 2023 - MM is a hematological malignancy, supposed mainly not curable, except for some exceptional patients, despite the availability of numerous new drugs. The patients are highly susceptible to infections, both bacterial and viral, due to a defect immun...
https://clinicaltrials.gov/ct2/show/NCT04499573
Feb 22nd, 2023 - The main objectives of the study are: To investigate the incidence of adverse events of grade 3-5 within after CD19/CD22 CAR lymphocyte infusion by day 28, To evaluate the incidence of complete remission and MRD-negative CR by day 28 To evaluate t...
https://clinicaltrials.gov/ct2/show/NCT02579967
Feb 17th, 2023 - Background: Primary immunodeficiency diseases (PIDs) are conditions associated with major quantitative or qualitative immunologic abnormalities that are, in most cases, due to defects in cells of hematopoietic origin Participants with PID can have...
https://clinicaltrials.gov/ct2/show/NCT00032513
Feb 8th, 2023 - Patients with chronic active Epstein-Barr virus (CAEBV) have (a) an illness that began as a primary infection with EBV or markedly elevated titers of antibodies to EBV, (b) histological evidence of organ disease, and (c) elevated EBV DNA levels in...
https://clinicaltrials.gov/ct2/show/NCT00967785
Feb 8th, 2023 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...
News 97 results
https://www.mdedge.com/hematology-oncology/article/262059/cll/b-cell-cancers-sparse-insight-preventing-infections
Randy Dotinga
Mar 28th, 2023 - Cases of acquired hypogammaglobulinemia are expected to rise, as patients live longer with such B-cell malignancies as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, and multiple myeloma. But there’s a striking shortage of research into.
https://www.onclive.com/view/treatments-branch-out-in-newly-diagnosed-and-relapsed-refractory-multiple-myeloma
Nov 17th, 2022 - Therapeutic strategies such as defining the optimal timing of autologous stem cell transplant (ASCT), implementing CAR T-cell agents, and introducing BCMA-directed bispecific antibodies are building on current standards of care (SOCs) in multiple ...
https://www.onclive.com/view/addressing-adverse-events-with-bispecific-antibodies-with-focus-on-crs-management
Oct 11th, 2022 - Transcript: Ajai Chari, MD:But putting that aside, let’s talk a little bit about adverse effects, too. Does anybody want to start with the adverse effects of BCMA [B-cell maturation antigen] as a class? And also distinguishing if you think there ...
https://www.onclive.com/view/bispecific-antibody-abbv-383-looks-to-fill-unmet-need-in-heavily-pretreated-multiple-myeloma
Aug 28th, 2022 - Promising safety and efficacy results were observed with the novel bispecific antibody ABBV-383 in patients with heavily pretreated relapsed or refractory multiple myeloma, according to updated results from a phase 1 trial (NCT03933735) presented ...
https://www.onclive.com/view/individualized-care-drives-treatment-focus-in-aml-dlbcl-and-cll
Jul 11th, 2022 - Future advances in leukemia and lymphoma treatment will arise from careful consideration of current management strategies, explained Ehab Atallah, MD, who emphasized the importance of framing future directions around present unmet needs, such as r...